Rafael Burgos Calderon, MD
Nephrology · Bayamon, PRNPI 1376653162
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 80.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $5,225 and has fallen 98.2% since, to $95 in 2025. Among nephrology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $153.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- AstraZeneca$839
- Bayer$216
- Bayer Puerto Rico Inc.$210
- Calliditas Therapeutics US Inc.$185
- Otsuka America Pharmaceutical, Inc.$138
- plus $652 from 10 others
Across 59 payments — averaging $6566.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$224K
- Eli Lilly Export S.A. Puerto Rico Branch$137K
- AstraZeneca$14K
- Eli Lilly$13K
What the payments were for
- Consulting fees$3,09027%
- Speaking & faculty fees$5,77050%
- Travel & lodging$220%
- Food & beverage$2,53622%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $9,278 |
| AstraZeneca | 23 | $839 |
| Bayer | 8 | $216 |
| Bayer Puerto Rico Inc. | 11 | $210 |
| Calliditas Therapeutics US Inc. | 2 | $185 |
| Otsuka America Pharmaceutical, Inc. | 2 | $138 |
| Vertex | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $125 |
| GSK | 1 | $125 |
| Travere Therapeutics, Inc. | 4 | $100 |
| Mallinckrodt Hospital Products Inc. | 1 | $60 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Amgen | 1 | $25 |
| Lilly USA, LLC | 1 | $25 |
| AbbVie | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,518 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 91 | $73,084 |
| KerendiaFinerenone | 30 | $31,622 |
| TradjentaLinagliptin | 13 | $8,944 |
| Pentoxifylline | 11 | $567 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $341 |
| Enalapril Maleate | 14 | $281 |
| Losartan Potassium | 25 | $274 |
| Allopurinol | 25 | $207 |
| Atorvastatin Calcium | 22 | $187 |
| Indapamide | 13 | $129 |
| Amlodipine Besylate | 19 | $115 |
| Famotidine | 19 | $115 |
| Metformin Hcl ErMetformin Hcl | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $839 | $73,08491 claims |
| BayerKerendia | $216 | $31,62230 claims |
| Boehringer IngelheimTradjenta | $18 | $8,94413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Bayamon
- Stephanie Colon-LopezBayamon$13K
- Clarylee OctavianiBayamon$6K
- Dennis Negron LucianoBayamon$3K
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Pedro ColtonSanturce$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.